Drugs / CMX-2043
CMX-2043
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02103959 | Jun 2014 → Sep 2015 | acute myocardial infarction, intermediate coronary syndrome | Ischemix, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00984802 | Feb 2010 → Mar 2011 | coronary artery disorder | Ischemix, LLC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMX-2043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02103959 ↗ |
| Known as | (r)-lip-l-glu-l-ala-oh | ChEMBL registry synonym — accepted as the source's own label CHEMBL3099551 ↗ |
| Known as | Lip-ea | ChEMBL registry synonym — accepted as the source's own label CHEMBL3099551 ↗ |
| Known as | R-lip-ea-oh | ChEMBL registry synonym — accepted as the source's own label CHEMBL3099551 ↗ |
| Modality | Small molecule | — CHEMBL3099551 ↗ |
| Route | Intravenous | “Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.” NCT00984802 ↗ |